YK 3-237 is primarily investigated for its potential in cancer research, particularly in the field of apoptosis induction. It is studied for its ability to target and inhibit specific pathways involved in cell survival, making it a candidate for developing novel anticancer therapies. Researchers are exploring its efficacy in inducing programmed cell death in various cancer cell lines, with a focus on its selectivity and minimal impact on healthy cells. Additionally, YK 3-237 is being examined for its role in overcoming drug resistance in certain cancers, offering a promising avenue for combination therapies. Its application extends to preclinical studies, where it serves as a tool to better understand the mechanisms of apoptosis and identify new targets for cancer treatment.